This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DERMAGRAFT® Approved In Canada For Treatment Of Diabetic Foot Ulcers

SAN DIEGO, September 5, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) has received regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

This approval gives Shire Regenerative Medicine the potential to extend availability of DERMAGRAFT to people with DFUs beyond the U.S., where it is currently available, and is an important first step for the company as it continues to develop its international expansion strategy.

"We're thrilled to have the opportunity to bring DERMAGRAFT to Canada, as we believe it plays an important role in the treatment of DFUs," said Matt Pauls, Vice President of Global Commercial Operations for Shire Regenerative Medicine. "This approval represents an important milestone in our strategic growth plan to build a global business that provides regenerative medicine solutions for people around the world with life-altering conditions."

This announcement follows Shire's recent commitment to build a new regenerative medicine campus in San Diego to gain increased capacity to meet future demand for DERMAGRAFT, as well as additional space and infrastructure to develop and manufacture new regenerative medicine products.

Shire Regenerative Medicine intends to make DERMAGRAFT available in Canada in Q1 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system, where the total population with diabetes was estimated to be 2.7 million people (7.6% of the total Canadian population) in 2010, and is projected to rise to 4.2 million people (10.8% of the total Canadian population) by 2020 [i]. In 2008, the Canadian Association of Wound Care estimated that 345,000 people with diabetes will develop a DFU in their lifetime and that DFUs were costing Canada's healthcare system more than $150 million annually. [ii]

Health Canada's approval of DERMAGRAFT on August 21, 2012 is based on a Canadian Device License Application submitted by Shire Regenerative Medicine in 2011.

About DFUs

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs